Literature DB >> 24894595

Novel homozygous SLC29A3 mutations among two unrelated Egyptian families with spectral features of H-syndrome.

Mohammad Al-Haggar1, Nanees Salem, Yahya Wahba, Nermin Ahmad, Laurence Jonard, Dina Abdel-Hady, Amany El-Hawary, Ashraf El-Sharkawy, Abdel-Rhman Eid, Amira El-Hawary.   

Abstract

OBJECTIVES: H syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders. We aim to screen for pathogenic SLC29A3 mutations in two unrelated Egyptian families with affected siblings of these overlapping syndromes.
METHODS: Clinical, laboratory, histopathological, and radiological characteristics of individuals probably diagnosed as H and/or PHID syndrome were reported. Mutation analysis of SLC29A3 gene was performed for all members of the two Egyptian families.
RESULTS: All affected individuals were females; proband of family-I (A1961) displayed overlapping features of H syndrome and PHID, while her younger brother (A1962) was asymptomatic. A1961 presented with previously undescribed features; absent pectoralis major muscle and a supracondylar bony spur in left humerus. In family-II, probands (A1965 and A1966) had clinical features consistent with classical H syndrome with unique early onset of cutaneous phenomena at birth. Mutation analysis of SLC29A3 revealed homozygous mutation previously reported in literature c.1279G>A [p.G427S] in A1961 and unexpectedly in the asymptomatic A1962 of family-I. Probands of family-II were homozygous for a novel mutation c.401G>A [p.R134H], in the same codon that was published in an Indian boy [p.R134C].
CONCLUSIONS: We emphasize the inter- and intra-familial genetic heterogeneity among Egyptian patients with overlapping features of SLC29A3 disorders. This suggests the presence of other factors like regulatory genes or epigenetic factors that may explain variable disease manifestations and severity.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Egyptian; H syndrome; SLC29A3 disorders

Mesh:

Substances:

Year:  2014        PMID: 24894595     DOI: 10.1111/pedi.12160

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  6 in total

1.  Mutation in the SLC29A3 Gene in an Egyptian Patient with H Syndrome: A Case Report and Review of Literature.

Authors:  Hala T El-Bassyouni; Manal M Thomas; Angie M S Tosson
Journal:  J Pediatr Genet       Date:  2019-09-30

2.  Molecular determinants of acidic pH-dependent transport of human equilibrative nucleoside transporter 3.

Authors:  Md Fazlur Rahman; Candice Askwith; Rajgopal Govindarajan
Journal:  J Biol Chem       Date:  2017-07-20       Impact factor: 5.157

3.  Identification of a novel mutation in solute carrier family 29, member 3 in a Chinese patient with H syndrome.

Authors:  Jia-Wei Liu; Nuo Si; Lian-Qing Wang; Ti Shen; Xue-Jun Zeng; Xue Zhang; Dong-Lai Ma
Journal:  Chin Med J (Engl)       Date:  2015-05-20       Impact factor: 2.628

4.  Adult stem cell deficits drive Slc29a3 disorders in mice.

Authors:  Sreenath Nair; Anne M Strohecker; Avinash K Persaud; Bhawana Bissa; Shanmugam Muruganandan; Craig McElroy; Rakesh Pathak; Michelle Williams; Radhika Raj; Amal Kaddoumi; Alex Sparreboom; Aaron M Beedle; Rajgopal Govindarajan
Journal:  Nat Commun       Date:  2019-07-03       Impact factor: 14.919

5.  Phenotypic intrafamilial variability including H syndrome and Rosai-Dorfman disease associated with the same c.1088G > A mutation in the SLC29A3 gene.

Authors:  Hamza Chouk; Mohamed Ben Rejeb; Lobna Boussofara; Haїfa Elmabrouk; Najet Ghariani; Badreddine Sriha; Ali Saad; Dorra H'Mida; Mohamed Denguezli
Journal:  Hum Genomics       Date:  2021-10-17       Impact factor: 4.639

6.  Patient with H syndrome, cardiogenic shock, multiorgan infiltration, and digital ischemia.

Authors:  Laura Ventura-Espejo; Inés Gracia-Darder; Silvia Escribá-Bori; Eva Regina Amador-González; Ana Martín-Santiago; Jan Ramakers
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-30       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.